DOTmed.com will be among the
the many exhibitors at SNM 2007.
the many exhibitors at SNM 2007.
SNM: Advances in Personalized Medicine on Agenda for 54th Annual Meeting
April 18, 2007
by Amanda Doreson, Project Manager, Old Employees
The potential of molecular imaging and therapy and the power of nuclear medicine-and their impact on patient care-will be explored as more than 4,000 people -- including doctors, technologists, scientists, pharmacists and DOTmed.com -- attend SNM's 54th Annual Meeting June 2-6 in Washington, D.C. SNM -- an international, multidisciplinary society of more than 16,000 molecular imaging and nuclear medicine professionals in 78 countries -- annually showcases research that promises to revolutionize health care.
"SNM has embarked on a mission to improve health care by advancing molecular imaging and therapy, and our program features an increased presence of related research," said SNM President Martin P. Sandler. "Molecular imaging-the use of state-of-the-art imaging technologies (such as PET, SPECT, MRI and others) to "photograph" biological targets or pathways in the body-and its therapy value will be at the forefront of 'personalized medicine,' eventually providing patient-specific information that allows tailored treatment of disease," he added.
"Nearly 2,000 scientific and technologist studies will be presented during this meeting, offering a look at molecular imaging and nuclear medicine research leading to improvements in the diagnosis and treatment of life-threatening cancer, heart disease and brain disorders," said Scientific Program Committee Chair Frederic H. Fahey. "A new feature this year is the InfoSNM program, which will allow attendees to participate in interactive computer presentations and educational offerings on the novel applications of computers and information science in molecular imaging and nuclear medicine," explained Fahey. Also new will be the Molecular Imaging Gateway, an area devoted specifically to this exciting field sponsored by the society's Molecular Imaging Center of Excellence.
"As molecular imaging becomes a significant force in clinical practice, SNM Technologist Section members will assume an expanded role in medical care, and this meeting brings us a look at that future," said SNMTS President D. Scott Holbrook. "Through research presented here, we can see the evolution of molecular imaging and nuclear medicine and how their advances will impact nuclear medicine technologists in the coming years," he added.
Two invited plenary addresses will be given at the meeting. John C. Gore of Vanderbilt University will present the Henry N. Wagner Jr. lecture on June 3, and James H. Thrall will present the Benedict Cassen Lecture on June 4. SNM and SNMTS will present more than 100 continuing education courses focusing on brain amyloid imaging, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, bone scanning, general nuclear medicine, reimbursement and coding and critical elements of care in radiopharmacy. More than 180 representatives from the industry's top product and service providers are participating in SNM's exhibit hall.
Representatives from the Food and Drug Administration will address the role of the investigational new drug (IND) in clinical research; they will provide a Radioactive Drug Research Committee update on June 5 and present updates on PET regulations on June 7. Additionally, representatives from the Nuclear Regulatory Commission will address "Running an NRC-Compliant Radiation Safety Program" on June 5. SNM members will take to Capitol Hill on June 5 to visit hometown representatives and talk about public policy issues.
On June 2, 12 categorical seminars, developed by members of SNM's various councils and centers of excellence, will be presented. These seminars will cover new directions in molecular imaging of the brain and heart, qualitative SPECT for molecular imaging, emerging clinical applications of SPECT/CT, radiopeptide imaging and therapy, molecular imaging and cancer therapy, pediatric radiotherapy, hot topics in PET/CT, multimodality molecular imaging, an assessment of nuclear cardiology, a PET/CT update in oncology and cardiology, and current issues and advances in nuclear medicine.
To register for the meeting, visit the SNM Web site at www.snm.org/am.
About SNM-Advancing Molecular Imaging and Therapy
SNM is holding its 54th Annual Meeting June 2-6 at the Washington, D.C., Convention Center. Session topics for the 2007 meeting include brain amyloid imaging, hybrid imaging, molecular imaging in clinical drug development and evaluation, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, general nuclear medicine, critical elements of care in radiopharmacy and more.
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced-and continue to explore-biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.
"SNM has embarked on a mission to improve health care by advancing molecular imaging and therapy, and our program features an increased presence of related research," said SNM President Martin P. Sandler. "Molecular imaging-the use of state-of-the-art imaging technologies (such as PET, SPECT, MRI and others) to "photograph" biological targets or pathways in the body-and its therapy value will be at the forefront of 'personalized medicine,' eventually providing patient-specific information that allows tailored treatment of disease," he added.
"Nearly 2,000 scientific and technologist studies will be presented during this meeting, offering a look at molecular imaging and nuclear medicine research leading to improvements in the diagnosis and treatment of life-threatening cancer, heart disease and brain disorders," said Scientific Program Committee Chair Frederic H. Fahey. "A new feature this year is the InfoSNM program, which will allow attendees to participate in interactive computer presentations and educational offerings on the novel applications of computers and information science in molecular imaging and nuclear medicine," explained Fahey. Also new will be the Molecular Imaging Gateway, an area devoted specifically to this exciting field sponsored by the society's Molecular Imaging Center of Excellence.
"As molecular imaging becomes a significant force in clinical practice, SNM Technologist Section members will assume an expanded role in medical care, and this meeting brings us a look at that future," said SNMTS President D. Scott Holbrook. "Through research presented here, we can see the evolution of molecular imaging and nuclear medicine and how their advances will impact nuclear medicine technologists in the coming years," he added.
Two invited plenary addresses will be given at the meeting. John C. Gore of Vanderbilt University will present the Henry N. Wagner Jr. lecture on June 3, and James H. Thrall will present the Benedict Cassen Lecture on June 4. SNM and SNMTS will present more than 100 continuing education courses focusing on brain amyloid imaging, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, bone scanning, general nuclear medicine, reimbursement and coding and critical elements of care in radiopharmacy. More than 180 representatives from the industry's top product and service providers are participating in SNM's exhibit hall.
Representatives from the Food and Drug Administration will address the role of the investigational new drug (IND) in clinical research; they will provide a Radioactive Drug Research Committee update on June 5 and present updates on PET regulations on June 7. Additionally, representatives from the Nuclear Regulatory Commission will address "Running an NRC-Compliant Radiation Safety Program" on June 5. SNM members will take to Capitol Hill on June 5 to visit hometown representatives and talk about public policy issues.
On June 2, 12 categorical seminars, developed by members of SNM's various councils and centers of excellence, will be presented. These seminars will cover new directions in molecular imaging of the brain and heart, qualitative SPECT for molecular imaging, emerging clinical applications of SPECT/CT, radiopeptide imaging and therapy, molecular imaging and cancer therapy, pediatric radiotherapy, hot topics in PET/CT, multimodality molecular imaging, an assessment of nuclear cardiology, a PET/CT update in oncology and cardiology, and current issues and advances in nuclear medicine.
To register for the meeting, visit the SNM Web site at www.snm.org/am.
About SNM-Advancing Molecular Imaging and Therapy
SNM is holding its 54th Annual Meeting June 2-6 at the Washington, D.C., Convention Center. Session topics for the 2007 meeting include brain amyloid imaging, hybrid imaging, molecular imaging in clinical drug development and evaluation, functional brain imaging in epilepsy and dementia, imaging instrumentation, infection imaging, lymphoma and thyroid cancer, cardiac molecular imaging, general nuclear medicine, critical elements of care in radiopharmacy and more.
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced-and continue to explore-biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.